Release Date: March 11, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: The 75 placements were impressive. What were the key drivers this quarter? A: Hadar Levy, CEO: The fourth quarter is typically strong for us, but enterprise accounts significantly contributed to our sales. We also saw increased demand for OCD treatments and higher utilization of our devices for MDD, anxious depression, and elderly patients.
Q: What's the latest on the accelerated treatment protocol timing? A: Hadar Levy, CEO: We are in the final recruitment stage and expect to complete the follow-up period soon. We aim to analyze the data and submit it to the FDA, with updates expected in the third quarter of 2025.
Q: Can you discuss the anticipated gross margin for 2025? A: Hadar Levy, CEO: We expect to maintain the gross margin at around 75%, similar to 2024. We are working on improvements but anticipate similar profitability levels for 2025.
Q: Are you seeing an increase in psychedelic therapy at current and new centers? A: Hadar Levy, CEO: Yes, more psychedelic clinics are integrating Deep TMS technology. These centers are interested in combining treatments, and we see potential growth through this channel.
Q: Any changes in the treatment paradigm for MDD and OCD with payers? A: Hadar Levy, CEO: The MDD treatment paradigm has improved, with fewer failures required for eligibility. For OCD, coverage is steadily growing, and we expect peers to continue embracing this technology.
Q: What can we expect regarding the 360 system in 2025? A: Hadar Levy, CEO: We plan to launch a multi-center trial in the US for the 360 system in the second half of 2025, focusing on AUD. We also aim to conduct feasibility studies for Alzheimer's and Parkinson's.
Q: Are there any acquisition opportunities given your cash position? A: Hadar Levy, CEO: We are focused on organic growth and strengthening partnerships with enterprise accounts. While not actively seeking acquisitions, we are open to complementary technologies that align with our Deep TMS system.
Q: Do you foresee any macroeconomic or geopolitical challenges impacting Brainsway in 2025? A: Hadar Levy, CEO: We don't see any current impact. Our business is primarily US-based, and we anticipate positive tailwinds from new indications in the mental health industry.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.